1. Michaud DS: Epidemiology of pancreatic cancer. Minerva Chir 2004; 59(2): 99-111.
2. Kędra B, Popiela T, Sierzega M et al.: Prognostic factors of long-term survival after resective procedures for pancreatic cancer. Hepatogastroenterol 2001; 48(42): 1762-66.
3. Tomimaru Y, Yano M, Takachi K et al.: Plasma D-dimer levels show correlation with number of lymph node metastases in patients with esophageal cancer. J Am Coll Surg 2006; 202: 139-45.
4. Yamashita H, Kitayama J, Kanno N et al.: Hyperfibrinogenemia is associated with lymphatic as well as hematogenous metastasis and worse clinical outcome in T2 gastric cancer. BMC Cancer 2006; 6: 147.
5. Gadducci A, Baicchi U, Marrai R et al.: Pretreatment plasma levels of and von Willebrand factor (vWF) in patients with operable cervical cancer: influence of surgical-pathological stage, tumor size, histologic type, and lymph node status. GynecolOncol 1993; 49: 354-58.
6. Dirix LY, Salgado R, Weytjens R et al.: Plasma fibrin D-dimer levels correlate with tumour volume, progression rate and survival in patients with 700 metastatic breast cancer. Br J Cancer 2002; 86: 389-95.
7. Lee JH, Ryu KW, Kim S et al.: Preoperative plasma fibrinogen levels in gastric cancer patients correlate with extent of tumor. Hepatogastroenterol 2004; 51: 1860-63.
8. Roche Y, Pasquier D, Rambeaud JJ et al.: Fibrinogen mediates bladder cancer cell migration in an ICAM-1-dependent pathway. Thromb Haemost 2003; 89: 1089-97.
9. O’Meara RA: Coagulative properties of cancers. Ir J Med Sci 1958; 394: 474-79.
10. Iwasaki T: Histological and experimental observations on the destruction of tumour cells the blood vessels. J Path Bact 1915; 20: 85.
11. Michaels L: Cancer incidence and mortality in patients having anticoagulant therapy. Lancet 1964; 2(7364): 832-35.
12. Piccioli A, Falanga A, Baccaglini U et al.: Cancer and venous thromboembolism. Semin ThrombHemost 2006; 32: 694-99.
13. Blomback B, Hessel B, Hogg D et al.: A two-step fibrinogen-fibrin transition in blood coagulation. Nature 1978; 275: 501-05.
14. Bayes-Genis A, Mateo J, Santaló M et al.: DDimer is an early diagnostic marker of coronary ischemia in patients with chest pain. Am Heart J 2000; 140(3): 379-84.
15. Rege KP, Jones S, Day J et al.: In proven deep vein thrombosis, a low positive D-Dimer score is a strong negative predictor for associated malignancy. Thromb Haemost 2004; 91: 1219-22.
16. Paneesha S, Cheyne E, French K et al.: High D-dimer levels at presentation in patients with venous thromboembolism is a marker of adverse clinical outcomes. Br J Haematol 2006; 135: 85-90.
17. Khorana AA, Fine RL: Pancreatic cancer and thromboembolic disease. Lancet Oncol 2004; 5(11): 655-63.
18. Wang ZH, Chang CC, Tai CJ: Deep vein thrombosis and pulmonary embolism in pancreatic cancer. J Cancer Res Pract 2011; 27 (4): 171-76.
19. Schutgens RE , Beckers MM, Haas FJ et al.: The predictive value of D-dimer measurement for cancer in patients with deep vein thrombosis. Haematologica 2005; 90: 214-19.
20. Xu G, Zhang YL, Huang W: Relationship between plasma D-dimer levels and clinicopathologic parameters in resectable colorectal cancer patients. World J Gastroenterol 2004; 10: 922-23.
21. Lippi G, Franchini M, Biasiutti C et al.: Increased D-dimer value and occult cancer in the absence of detectable thrombosis. Haematologica 2007; 92(4): 53-55.
22. Ay C, Dunkler D, Pirker R et al.: High D-dimer levels are associated with poor prognosis in cancer patients. Haematologica 2012; 97(8): 1158-64.
23. Khorana AA, Ahrendt SA, Ryan CK et al.: Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer. Clin Cancer Res 2007; 13(10): 2870-75.
24. Palumbo JS, Talmage KE , Massari JV et al.: Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood 2005; 105(1): 178-85.
25. Darwish AA, Sokal E, Stephenne X et al.: Permanent access to the portal system for cellular transplantation using an implantable port device. Liver Transpl 2004; 10: 1213-15.
26. Hogendorf P, Durczyński A, Kumor A et al.: Prostaglandin E2 (PGE2) in portal blood in patients with pancreatic tumor - a single institution series. J Invest Surg 2012; 25(1): 8-13.
27. Shibata T, Magari Y, Kamberi P et al.: Significance of urinary fibrin/fibrinogen degradation products (FDP) D-dimer measured by a highly sensitive ELISA method with a new monoclonal antibody (D-D E72) in various renal diseases. ClinNephrol 1995; 44(2): 91-95.
28. Spadaro A, Tortorella V, Morace C et al.: High circulating D-dimers are associated with ascites and hepatocellular carcinoma in liver cirrhosis. World J Gastroenterol 2008; 14(10): 1549-52.
29. Wang HY, Xiu DR, Li ZF et al.: Coagulation function in patients with pancreatic carcinoma. Chin Med J (Engl). 2009; 122(6): 697-700.
Comments (0)